FDA Approves Weight Loss Drug Wegovy for Liver Disease

About 6 percent of American adults have the disease, known as MASH.

Flags with the logo of Novo Nordisk, maker of Ozempic and Wegovy, in a file image. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images

The Food and Drug Administration (FDA) approved a weight loss drug called Wegovy for a liver disease, the agency announced on Aug. 18.

Wegovy is now approved for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that impacts approximately 6 percent of American adults, the FDA said in a statement.